The market has witnessed significant activity over the assets of
Haleon, a major player in the bio-tech market. Both
GSK and Pfizer decided to liquidate their stakes in Haleon through transactions worth
billions. The former was responsible for a sale amounting to approximately
£1.25B, which represented the end of the company's interest in Haleon. Pfizer, on the other hand, reduced its position from
32% to 24%, raising about
$3.5B. Despite this, Haleon's stock price witnessed a
temporary decrease. However, the company has seen accelerated revenue growth in the last year. This lockdown has resulted in
a significant share buyback, contributing to the financial growth of the company. Haleon announced the implementation of a
major share buyback scheme following strong FY results. The company's
successful Q1 earnings exceeded estimates. In addition, the company continued to attract interest from institutional investors, with
50% ownership recording at present. Despite challenges, it appears that the pressures faced by Haleon are
temporary. The company has also set
promising projections for the coming year.
Haleon Stocks News Analytics from Thu, 05 Oct 2023 07:00:00 GMT to Thu, 13 Jun 2024 11:57:03 GMT -
Rating 8
- Innovation 5
- Information 6
- Rumor 3
